Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies (SAFRAN)
Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.
We hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and/or an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.
The aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.
研究概览
地位
干预/治疗
详细说明
The investigators hypothesize that chronic overproduction of type I interferons (IFN-I) is driven by increased basal activation of nucleic acid-sensing pathways and/or heightened cellular responsiveness to endogenous nucleic acids, leading to sustained IFN-I signaling and persistent inflammation. The objective of the study is to characterize the IFN-I response by assessing both the interferon gene signature and plasma IFN-α levels following stimulation of PBMCs with a panel of DNA- and RNA-sensing pathway-specific ligands.
The SAFRAN study protocol comprises two study visits for patients: a mandatory Visit 1 (V1) and an optional Visit 2 (V2), the performance of which depends on the results obtained at V1. Healthy control participants will undergo Visit 1 (V1) only.
During Visit 1 (V1), the investigator will perform a clinical assessment as part of routine disease management. Disease activity will be evaluated using validated clinical scoring systems. For patients with systemic lupus erythematosus (SLE), disease activity will be assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For patients with systemic sclerosis, skin involvement will be evaluated using the modified Rodnan Skin Score (mRSS). In addition, disease activity will be assessed in all patients using the Physician Global Assessment (PGA) scale.
During Visit 2 (V2), patients in whom an abnormality in interferon signaling is identified through the in vitro assays will undergo additional blood sampling during a routine follow-up visit conducted as part of standard clinical care. An additional blood volume of 12 mL will be collected to further characterize the abnormality detected in the previous sample (V1), within 12 months of the initial assessment.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Alexandre BELOT, MD, PhD
- 电话号码:+3342786126
- 邮箱:Alexandre.belot@chu-lyon.fr
研究联系人备份
- 姓名:Samira PLASSART
- 电话号码:+33427855442
- 邮箱:samira.plassart@chu-lyon.fr
学习地点
-
-
-
Bron、法国、69500
- Hôpital Femme-Mère-Enfant
-
接触:
- Alexandre BELOT, MD, Ph D
- 电话号码:+33427856126
- 邮箱:alexandre.belot@chu-lyon.fr
-
首席研究员:
- Alexandre BELOT, MD, Ph D
-
Lyon、法国、69003
- Hôpital Edouard Herriot
-
接触:
- Thomas BARBA, MD
- 电话号码:+33472119583
- 邮箱:thomas.barba@chu-lyon.fr
-
首席研究员:
- Thomas BARBA, MD
-
Oullins、法国、69495
- Centre Hospitalier Lyon-Sud
-
接触:
- Maël RICHARD, MD
- 电话号码:+33478843973
- 邮箱:mael.richard@chu-lyon.fr
-
首席研究员:
- Mael RICHARD, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Patient
-
Patient followed at the Hospices Civils de Lyon (HCL) for their disease.
-
Patient aged over 6 years and under 60 years.
-
Body weight ≥ 25 kg.
-
Patient with a confirmed diagnosis of
- Systemic lupus erythematosus
- Myositis, histologically confirmed or not
- Systemic sclerosis,
- Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al.
- Genetically confirmed monogenic lupus or monogenic interferonopathy.
-
Patient, parents, or legal guardians informed about the study and having signed the informed consent form.
Healthy Volunteer Participants
- Subjects aged over 6 years and under 60 years.
- Body weight greater than or equal to 25 kg.
- Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.
Exclusion Criteria:
Patient
- documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling
- Subjects currently participating in an interventional drug study
- Vaccination within 1 month prior to sampling
- Pregnant, parturient, or breastfeeding women
- Individuals deprived of liberty by judicial or administrative decision
- Individuals receiving psychiatric care
- Individuals admitted to a healthcare or social care institution for reasons other than participation in the research
- Adults subject to a legal protection measure
- Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system
Healthy Volunteer Participants
- Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection.
- Participant with a long-term chronic disease (ALD) or any chronic medical condition.
- Participant with a primary immunodeficiency.
- Vaccination within 1 month prior to sample collection.
- History of neoplasia (< 5 years) or ongoing neoplastic disease.
- Pregnant, parturient, or breastfeeding women.
- Individuals deprived of liberty by a judicial or administrative decision.
- Individuals receiving psychiatric care.
- Individuals admitted to a health or social care institution for purposes other than participation in research.
- Adults subject to a legal protection measure (guardianship or curatorship).
- Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Patients
Patients with systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies |
Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL). |
|
其他:control
Healthy volunteer |
Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL). |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
IFN-I signature score
大体时间:Day 1 and Month 12 (if applicable)
|
The interferon signature assessed by transcriptomic analysis and IFN-α concentrations measured using the Simoa assay will be compared across the different disease groups and with healthy volunteers. |
Day 1 and Month 12 (if applicable)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical phenotype
大体时间:Day 1 and Month 12 (if applicable)
|
Correlation between the extent of specific organ involvement and the activation of nucleic acid-sensing pathways, assessed by the levels of IFN-α production. |
Day 1 and Month 12 (if applicable)
|
|
plasma IFN-α concentration
大体时间:Day 1 and Month 12 (if applicable)
|
In vitro change in the IFN signature and IFN-α production in patients' PBMCs after exposure to selective inhibitors of overactivated IFN-I signaling pathways |
Day 1 and Month 12 (if applicable)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.